Predictive value of FHIT, p27, and pERK1/ERK2 in salivary gland carcinomas: a retrospective study
- 90 Downloads
The aim of this study was to investigate the predictive value of the biomarkers FHIT, p27, and pERK1/ERK2 in salivary gland carcinomas.
Material and methods
Immunohistochemical staining of FHIT, p27, and pERK1/ERK2 of 265 patients with salivary gland carcinomas was conducted, and associations with clinico-histopathological data, overall survival, and disease-specific survival were examined.
Expression of FHIT (quick score 98.7 vs. 206.4) and p27 (QS 187.3 vs. 244.8) was significantly lower in carcinomas compared to non-tumor control tissue. Loss of FHIT frequently occurred in ACC (55.2%), SDC (68.2%), and SCC (100%). In the totality of tumors, loss of FHIT expression was found in 46.7% (106/227) and was significantly associated with advanced T stage and UICC stage, high-grade histology, loss of p27, PI3K, and survivin. FHIT positivity went along with significantly better overall and disease-specific survival. Negativity of p27 occurred in 28.7% (70/244) of tumors, particularly in SDC (54.4%) and SCC (50%). In the totality of tumors, p27 was associated with advanced patient age, high-grade histology, PI3K, survivin as well as better overall and disease-specific survival (p < 0.05). Positive pERK1/ERK2 expression correlated with positive survivin expression but did not affect overall survival in the totality of tumors. In mucoepidermoid carcinomas, pERK1/ERK2 expression was associated with low-grade malignancy, positive nuclear survivin, and better disease-specific survival.
Loss of FHIT and p27 characterizes aggressive tumor growth and unfavorable prognosis in salivary gland cancer.
The results may help to stratify patient-specific therapies according to individual tumor characteristics.
KeywordsSalivary gland carcinoma FHIT p27 pERK1/ERK2
We wish to thank Rudolf Jung for his excellent immunohistochemical stainings.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
The study has been performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
For this type of study, formal consent is not required.
- 4.Dincer N, Tezel GG, Sungur A, Himmetoglu C, Huebner K, Guler G (2010) Study of FHIT and WWOX expression in mucoepidermoid carcinoma and adenoid cystic carcinoma of salivary gland. Oral Oncol 46:195–199. https://doi.org/10.1016/j.oraloncology.2009.12.003 CrossRefPubMedGoogle Scholar
- 5.Semba S, Trapasso F, Fabbri M, McCorkell KA, Volinia S, Druck T, Iliopoulos D, Pekarsky Y, Ishii H, Garrison PN, Barnes LD, Croce CM, Huebner K (2006) Fhit modulation of the Akt-survivin pathway in lung cancer cells: Fhit-tyrosine 114 (Y114) is essential. Oncogene 25:2860–2872. https://doi.org/10.1038/sj.onc.1209323 CrossRefPubMedGoogle Scholar
- 9.Handra-Luca A, Ruhin B, Lesty C, Fouret P (2006) P27, SKP2, and extra-cellular signal-related kinase signalling in human salivary gland mucoepidermoid carcinoma. Oral Oncol 42:1005–1010. https://doi.org/10.1016/j.oraloncology.2005.12.022/c CrossRefPubMedGoogle Scholar
- 12.Barnes L, Eveson J, Reichart P, Sidransky D (2005) Pathology and genetics of head and neck tumours. World Health Organization classification of Tumours. IARC, LyonGoogle Scholar
- 15.Milanes-Yearsley M, Hammond ME, Pajak TF, Cooper JS, Chang C, Griffin T, Nelson D, Laramore G, Pilepich M (2002) Tissue micro-array: a cost and time-effective method for correlative studies by regional and national cancer study groups. Mod Pathol 15:1366–1373. https://doi.org/10.1097/01.MP.0000036345.18944.22 CrossRefPubMedGoogle Scholar
- 16.Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, Rougier P, Lievre A, Landi B, Boige V, Ducreux M, Ychou M, Bibeau F, Bouche O, Reid J, Stone S, Penault-Llorca F (2009) Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 27:5924–5930. https://doi.org/10.1200/JCO.2008.21.6796 CrossRefPubMedGoogle Scholar
- 19.Dumon K, Ishii H, Vecchione A, Trapasso F, Baldassarre G, Chakrani F, Druck T, Rosato E, Williams N, Baffa R, During M, Huebner K, Croce C (2001) Fragile histidine triad expression delays tumor development and induces apoptosis in human pancreatic cancer1. Cancer Res 61:4827–4836PubMedGoogle Scholar
- 20.Huang Q, Liu Z, Xie F, Liu C, Shao F, Zhu CL, Hu S (2014) Fragile histidine triad (FHIT) suppresses proliferation and promotes apoptosis in cholangiocarcinoma cells by blocking PI3K-Akt pathway. ScientificWorldJournal 2014:179698. https://doi.org/10.1155/2014/179698 CrossRefPubMedPubMedCentralGoogle Scholar
- 23.Sarli L, Bottarelli L, Azzoni C, Campanini N, Di Cola G, Barilli AL, Marchesi F, Mazzeo A, Salvemini C, Morari S, Di Mauro D, Donadei E, Necchi F, Roncoroni L, Bordi C (2006) Loss of p27 expression and microsatellite instability in sporadic colorectal cancer. Surg Oncol 15:97–106. https://doi.org/10.1016/j.suronc.2006.09.002 CrossRefPubMedGoogle Scholar
- 26.Milde-Langosch K, Bamberger AM, Rieck G, Grund D, Hemminger G, Muller V, Loning T (2005) Expression and prognostic relevance of activated extracellular-regulated kinases (ERK1/2) in breast cancer. Br J Cancer 92:2206–2215. https://doi.org/10.1038/sj.bjc.6602655 CrossRefPubMedPubMedCentralGoogle Scholar
- 27.Lujan B, Hakim S, Moyano S, Nadal A, Caballero M, Diaz A, Valera A, Carrera M, Cardesa A, Alos L (2010) Activation of the EGFR/ERK pathway in high-grade mucoepidermoid carcinomas of the salivary glands. Br J Cancer 103:510–516. https://doi.org/10.1038/sj.bjc.6605788 CrossRefPubMedPubMedCentralGoogle Scholar
- 29.Ettl T, Baader K, Stiegler C, Muller M, Agaimy A, Zenk J, Kuhnel T, Gosau M, Zeitler K, Schwarz S, Brockhoff G (2012) Loss of PTEN is associated with elevated EGFR and HER2 expression and worse prognosis in salivary gland cancer. Br J Cancer 106:719–726. https://doi.org/10.1038/bjc.2011.605 CrossRefPubMedPubMedCentralGoogle Scholar
- 31.Ach T, Zeitler K, Schwarz-Furlan S, Baader K, Agaimy A, Rohrmeier C, Zenk J, Gosau M, Reichert TE, Brockhoff G, Ettl T (2013) Aberrations of MET are associated with copy number gain of EGFR and loss of PTEN and predict poor outcome in patients with salivary gland cancer. Virchows Arch 462:65–72. https://doi.org/10.1007/s00428-012-1358-0 CrossRefPubMedGoogle Scholar